Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)

Otitis Media With Effusion in Children Clinical Trial

Official title:

Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02432105
• Other study ID #: EXE844b-C001
• Status: Completed
• Phase: Phase 3
• Start date: June 25, 2015
• Est. completion date: June 15, 2016

Study information

• Verified date: June 2017
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate EXE844 plus tympanostomy tubes compared to tympanostomy tubes only based on sustained clinical cure at end-of-therapy (EOT).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 470
• Est. completion date: June 15, 2016
• Est. primary completion date: June 15, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 12 Years

Eligibility

Inclusion Criteria:

• Recurrent acute otitis media (RAOM) or chronic otitis media with effusion (COME) and eligible for bilateral myringotomy and tympanostomy tube insertion.

• Suspected bacterial infection at time of surgery in at least 1 ear.

• Willing to refrain from water immersion of the ears following surgery without the use of adequate ear protection during swimming, bathing, showering and other water-related activities.

• Legally Authorized Representative (LAR) must read and sign the informed consent.

• Parent or caregiver must agree to comply with the requirements of the study and administer study medication as directed, complete required study visits, and comply with the protocol.

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Previous otologic or otologic-related surgery within the past 30 days or ongoing complications.

• Middle ear pathology in either ear other than otitis media.

• Current acute otitis externa (AOE), malignant otitis externa (MOE) or other conditions which could interfere with evaluation of the study drug.

• Any systemic disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study based upon assessment by the Investigator.

• Known or suspected allergy or hypersensitivity to quinolones or other active or inactive ingredients present in the medications to be used in the study.

• Other protocol-specified exclusion criteria may apply.

Related Conditions & MeSH terms

• Otitis
• Otitis Media
• Otitis Media Recurrent
• Otitis Media with Effusion
• Otitis Media With Effusion in Children

Intervention

Drug:
• EXE844 Sterile Otic Suspension, 0.3%

Procedure:
• Tympanostomy Tube Insertion
Surgical procedure for treating pediatric cases of recurrent or chronic otitis media

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alcon Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects With Sustained Clinical Cure at Day 8	A sustained clinical cure was attained if otorrhea was absent in the study ear at Day 8 (EOT) per the Investigator assessment and continued to be absent through the end of the study. Participants were considered a treatment failure if, at any time during the study, an alternative therapy was initiated to treat the postsurgical infection. All participants with missing or indeterminate outcomes were considered a failure (same as baseline observation carried forward).	Day 8
Secondary	Percentage of Subjects With Microbiological Success at Day 14	Microbiological success was attained if all pretherapy bacteria were absent in the study ear for the Test-of-Cure (TOC) (Day 14) specimen. Participants were considered a treatment failure if, at any time during the study, an alternative therapy was initiated to treat the postsurgical infection. All participants with missing or indeterminate outcomes were considered a failure (same as baseline observation carried forward).	Day 14
Secondary	Time to Cessation of Otorrhea	Time (in days) to the cessation of otorrhea in the enrolled ear(s) was calculated as the number of days from the day of surgery to the absence of otorrhea (ie, no discharge) as reported by the parent/caregiver via the BID diary. Participants were considered a treatment failure if, at any time during the course of the study, an alternative therapy was initiated to treat the postsurgical infection. All participants with missing or indeterminate outcomes were considered a failure (same as baseline observation carried forward).	Up to Day 14

External Links

•   Results from the Novartis Clinical Trial Results Website